Tumor-specific cytotoxic T-cell (CTL) responses in the tumor were significantly enhanced in IL-33-OL-33 wild-type (WT) tumor-bearing (TB) mice but not in IL-33-treated Batf3−/− TB mice (Fig. 1B). This evidence concerns the gene IL33 and neoplasm.